{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:36:12Z","timestamp":1790951772632,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fecal calprotectin (FC) is a promising biomarker for diagnosis and treatment of inflammatory bowel disease, ulcerative colitis (UC), and Crohn\u2019s disease. An enzyme immunoassay (EIA) is widely used for FC detection, though the considerable lag time, up to several days, causes clinical management delay. This study was performed to examine the new rapid kit fCAL-turbo, which is based on a particle-enhanced turbidimetric immunoassay (15 min), by comparing FC values with other EIAs (EliA, PhiCal, B\u00fchlmann) and endoscopic scores. Using 94 samples, fCAL-turbo showed strong significant positive correlations with the other kits (Spearman\u2019s r\u2009=\u20090.9178\u20130.9886). Of 74 UC patients, 69 underwent an endoscopy and fCAL-turbo reflected endoscopic activity with a moderate correlation with Mayo endoscopic subscore (MES) (r\u2009=\u20090.6945, others r\u2009=\u20090.6682\u20130.7013). Receiver operating characteristic analyses based on MES 0 versus 1\u20133 showed a similar efficacy as compared to the other kits (cut-off and area under the curve: 89.70 \u00b5g\/g and 0.8592, respectively, others 62.35\u2013138.4 \u00b5g\/g and 0.8280\u20130.8611, respectively). Furthermore, multiple regression analysis confirmed that fCAL-turbo results significantly contributed to prediction of MES 0 with a higher t-value as compared to the other biomarkers. fCAL-turbo showed strong correlations with the other kits and also demonstrated excellent performance for predicting endoscopic remission of UC.<\/jats:p>","DOI":"10.1038\/s41598-024-51580-z","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T12:02:28Z","timestamp":1705579348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Validation of rapid fecal calprotectin assay using particle enhanced turbidimetric immunoassay for inflammatory bowel disease"],"prefix":"10.1038","volume":"14","author":[{"given":"Akihiko","family":"Oka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousaku","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Fukuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihisa","family":"Ishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muyiwa","family":"Awoniyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"51580_CR1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature06005","volume":"448","author":"RJ Xavier","year":"2007","unstructured":"Xavier, R. J. & Podolsky, D. K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427\u2013434 (2007).","journal-title":"Nature"},{"key":"51580_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1053\/j.gastro.2020.09.056","volume":"160","author":"M Lee","year":"2021","unstructured":"Lee, M. & Chang, E. B. Inflammatory bowel diseases (IBD) and the microbiome\u2014Searching the crime scene for clues. Gastroenterology 160, 524\u2013537 (2021).","journal-title":"Gastroenterology"},{"key":"51580_CR3","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 390, 2769\u20132778 (2017).","journal-title":"Lancet"},{"key":"51580_CR4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","volume":"13","author":"C Maaser","year":"2019","unstructured":"Maaser, C. et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J. Crohn\u2019s Colitis 13, 144-164K (2019).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"51580_CR5","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","volume":"141","author":"JF Colombel","year":"2011","unstructured":"Colombel, J. F. et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141, 1194\u20131201 (2011).","journal-title":"Gastroenterology"},{"key":"51580_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/apt.13475","volume":"43","author":"SC Shah","year":"2016","unstructured":"Shah, S. C., Colombel, J.-F., Sands, B. E. & Narula, N. Systematic review with meta-analysis: Mucosal healing is associated with improved long-term outcomes in Crohn\u2019s disease. Aliment. Pharmacol. Ther. 43, 317\u2013333 (2016).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"51580_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/apt.12221","volume":"37","author":"GD Naismith","year":"2013","unstructured":"Naismith, G. D. et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn\u2019s disease. Aliment. Pharmacol. Ther. 37, 613\u2013621 (2013).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"51580_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/ibd.21751","volume":"18","author":"P De Cruz","year":"2012","unstructured":"De Cruz, P. et al. Characterization of the gastrointestinal microbiota in health and inflammatory bowel disease. Inflamm. Bowel Dis. 18, 372\u2013390 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"51580_CR9","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner, D. et al. STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160, 1570\u20131583 (2021).","journal-title":"Gastroenterology"},{"key":"51580_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MPG.0000000000000939","volume":"62","author":"A Heida","year":"2016","unstructured":"Heida, A., Holtman, G. A., Lisman-van Leeuwen, Y., Berger, M. Y. & van Rheenen, P. F. Avoid endoscopy in children with suspected inflammatory bowel disease who have normal calprotectin levels. J. Pediatr. Gastroenterol. Nutr. 62, 47\u201349 (2016).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"51580_CR11","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3390\/life11121375","volume":"11","author":"K Wagatsuma","year":"2021","unstructured":"Wagatsuma, K., Yokoyama, Y. & Nakase, H. Role of biomarkers in the diagnosis and treatment of inflammatory bowel disease. Life 11, 1375 (2021).","journal-title":"Life"},{"key":"51580_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/bs.acc.2018.07.005","volume":"87","author":"RM Ayling","year":"2018","unstructured":"Ayling, R. M. & Kok, K. Fecal calprotectin. Adv. Clin. Chem. 87, 161\u2013190 (2018).","journal-title":"Adv. Clin. Chem."},{"key":"51580_CR13","first-page":"1","volume":"2012","author":"JM Lee","year":"2012","unstructured":"Lee, J. M. et al. Update of faecal markers of inflammation in children with cystic fibrosis. Mediat. Inflamm. 2012, 1\u20136 (2012).","journal-title":"Mediat. Inflamm."},{"key":"51580_CR14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/bmj.c3369","volume":"341","author":"PF Van Rheenen","year":"2010","unstructured":"Van Rheenen, P. F., Van De Vijver, E. & Fidler, V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-analysis. BMJ 341, 188 (2010).","journal-title":"BMJ"},{"key":"51580_CR15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ajg.2015.6","volume":"110","author":"SB Menees","year":"2015","unstructured":"Menees, S. B., Powell, C., Kurlander, J., Goel, A. & Chey, W. D. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am. J. Gastroenterol. 110, 444\u2013454 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"51580_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12876-016-0462-z","volume":"16","author":"K Kawashima","year":"2016","unstructured":"Kawashima, K. et al. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol. 16, 47 (2016).","journal-title":"BMC Gastroenterol."},{"key":"51580_CR17","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1097\/MIB.0000000000001202","volume":"23","author":"K Kawashima","year":"2017","unstructured":"Kawashima, K. et al. Fecal calprotectin more accurately predicts endoscopic remission of Crohn\u02bcs disease than serological biomarkers evaluated using balloon-assisted enteroscopy. Inflamm. Bowel Dis. 23, 2027\u20132034 (2017).","journal-title":"Inflamm. Bowel Dis."},{"key":"51580_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3164\/jcbn.18-92","volume":"64","author":"H Sonoyama","year":"2019","unstructured":"Sonoyama, H. et al. Capabilities of fecal calprotectin and blood biomarkers as surrogate endoscopic markers according to ulcerative colitis disease type. J. Clin. Biochem. Nutr. 64, 265\u2013270 (2019).","journal-title":"J. Clin. Biochem. Nutr."},{"key":"51580_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/342751","volume":"2014","author":"K Kawashima","year":"2014","unstructured":"Kawashima, K. et al. Therapeutic efficacy of pH-dependent release formulation of mesalazine on active ulcerative colitis resistant to time-dependent release formulation: Analysis of fecal calprotectin concentration. Biomed Res. Int. 2014, 1\u20136 (2014).","journal-title":"Biomed Res. Int."},{"key":"51580_CR20","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"JF Colombel","year":"2017","unstructured":"Colombel, J. F. et al. Effect of tight control management on Crohn\u2019s disease (CALM): A multicentre, randomised, controlled phase 3 trial. Lancet 390, 2779\u20132789 (2017).","journal-title":"Lancet"},{"key":"51580_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MIB.0b013e3182810066","volume":"19","author":"AM Schoepfer","year":"2013","unstructured":"Schoepfer, A. M. et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm. Bowel Dis. 19, 332\u2013341 (2013).","journal-title":"Inflamm. Bowel Dis."},{"key":"51580_CR22","first-page":"26","volume":"9","author":"A Lasson","year":"2015","unstructured":"Lasson, A. et al. The intra-individual variability of faecal calprotectin: A prospective study in patients with active ulcerative colitis. J. Crohn\u2019s Colitis 9, 26\u201332 (2015).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"51580_CR23","doi-asserted-by":"publisher","first-page":"11086","DOI":"10.1038\/s41598-021-90441-x","volume":"11","author":"E Yasutomi","year":"2021","unstructured":"Yasutomi, E. et al. Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease. Sci. Rep. 11, 11086 (2021).","journal-title":"Sci. Rep."},{"key":"51580_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.5009\/gnl17013","volume":"12","author":"S Hiraoka","year":"2018","unstructured":"Hiraoka, S. et al. Fecal immunochemical test and fecal calprotectin results show different profiles in disease monitoring for ulcerative colitis. Gut Liver 12, 142\u2013148 (2018).","journal-title":"Gut Liver"},{"key":"51580_CR25","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.cgh.2019.07.054","volume":"18","author":"M Naganuma","year":"2020","unstructured":"Naganuma, M. et al. Significance of conducting 2 types of fecal tests in patients with ulcerative colitis. Clin. Gastroenterol. Hepatol. 18, 1102-1111.e5 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"51580_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3904\/kjim.2016.324","volume":"34","author":"YW Lee","year":"2019","unstructured":"Lee, Y. W. et al. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity. Korean J. Intern. Med. 34, 72\u201380 (2019).","journal-title":"Korean J. Intern. Med."},{"key":"51580_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac095","author":"K Kawashima","year":"2022","unstructured":"Kawashima, K. et al. Low fecal calprotectin predicts histological healing in patients with ulcerative colitis with endoscopic remission and leads to prolonged clinical remission. Inflamm. Bowel Dis. https:\/\/doi.org\/10.1093\/ibd\/izac095 (2022).","journal-title":"Inflamm. Bowel Dis."},{"key":"51580_CR28","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/MIB.0000000000001082","volume":"23","author":"A Heida","year":"2017","unstructured":"Heida, A., Park, K. T. & van Rheenen, P. F. Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: A systematic review and practical guide. Inflamm. Bowel Dis. 23, 894\u2013902 (2017).","journal-title":"Inflamm. Bowel Dis."},{"key":"51580_CR29","doi-asserted-by":"publisher","first-page":"030710","DOI":"10.11613\/BM.2017.030710","volume":"27","author":"B Noebauer","year":"2017","unstructured":"Noebauer, B., Ramic, L., Konstantin, A., Zachbauer, C. & Einwallner, E. Analytical evaluation of a fully automated immunoassay for faecal calprotectin in a paediatric setting. Biochem. Med. 27, 030710 (2017).","journal-title":"Biochem. Med."},{"key":"51580_CR30","doi-asserted-by":"publisher","first-page":"e22061","DOI":"10.1002\/jcla.22061","volume":"31","author":"T Nilsen","year":"2017","unstructured":"Nilsen, T., Sunde, K., Hansson, L.-O., Havelka, A. M. & Larsson, A. A novel turbidimetric immunoassay for fecal calprotectin optimized for routine chemistry analyzers. J. Clin. Lab. Anal. 31, e22061 (2017).","journal-title":"J. Clin. Lab. Anal."},{"key":"51580_CR31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","volume":"11","author":"F Magro","year":"2017","unstructured":"Magro, F. et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J. Crohn\u2019s Colitis 11, 649\u2013670 (2017).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"51580_CR32","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet, L. et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am. J. Gastroenterol. 110, 1324\u20131338 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"51580_CR33","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.cgh.2013.11.005","volume":"12","author":"G Bouguen","year":"2014","unstructured":"Bouguen, G., Levesque, B. G., Pola, S., Evans, E. & Sandborn, W. J. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn\u2019s disease. Clin. Gastroenterol. Hepatol. 12, 978\u2013985 (2014).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"51580_CR34","first-page":"1","volume":"2018","author":"L Hodgson-Parnell","year":"2018","unstructured":"Hodgson-Parnell, L., Spence, O. & Chapple, K. Solitary juvenile polyp as a cause of elevated faecal calprotectin in an adult. BMJ Case Rep. 2018, 1\u20132 (2018).","journal-title":"BMJ Case Rep."},{"key":"51580_CR35","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.3748\/wjg.v27.i16.1828","volume":"27","author":"M State","year":"2021","unstructured":"State, M. et al. Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review. World J. Gastroenterol. 27, 1828\u20131840 (2021).","journal-title":"World J. Gastroenterol."},{"key":"51580_CR36","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1515\/cclm-2016-1012","volume":"55","author":"M Oyaert","year":"2017","unstructured":"Oyaert, M. et al. Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease. Clin. Chem. Lab. Med. 55, 1564\u20131573 (2017).","journal-title":"Clin. Chem. Lab. Med."},{"key":"51580_CR37","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1097\/MIB.0000000000000057","volume":"20","author":"J-F Lin","year":"2014","unstructured":"Lin, J.-F. et al. Meta-analysis: Fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm. Bowel Dis. 20, 1407\u20131415 (2014).","journal-title":"Inflamm. Bowel Dis."},{"key":"51580_CR38","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1002\/ibd.22917","volume":"18","author":"G D\u2019Haens","year":"2012","unstructured":"D\u2019Haens, G. et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm. Bowel Dis. 18, 2218\u20132224 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"51580_CR39","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ajg.2015.120","volume":"110","author":"MH Mosli","year":"2015","unstructured":"Mosli, M. H. et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and meta-analysis. Am. J. Gastroenterol. 110, 802\u2013819 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"51580_CR40","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/apt.15662","volume":"51","author":"F D\u2019Amico","year":"2020","unstructured":"D\u2019Amico, F., Bonovas, S., Danese, S. & Peyrin-Biroulet, L. Review article: Faecal calprotectin and histologic remission in ulcerative colitis. Aliment. Pharmacol. Ther. 51, 689\u2013698 (2020).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"51580_CR41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1258\/acb.2012.011272","volume":"50","author":"SJ Whitehead","year":"2013","unstructured":"Whitehead, S. J., French, J., Brookes, M. J., Ford, C. & Gama, R. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann. Clin. Biochem. Int. J. Lab. Med. 50, 53\u201361 (2013).","journal-title":"Ann. Clin. Biochem. Int. J. Lab. Med."},{"key":"51580_CR42","doi-asserted-by":"publisher","first-page":"e0119574","DOI":"10.1371\/journal.pone.0119574","volume":"10","author":"F Li","year":"2015","unstructured":"Li, F. et al. Fecal calprotectin concentrations in healthy children aged 1\u201318 months. PLoS ONE 10, e0119574 (2015).","journal-title":"PLoS ONE"},{"key":"51580_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.23736\/S0031-0808.18.03405-5","volume":"60","author":"GP Caviglia","year":"2018","unstructured":"Caviglia, G. P. et al. Fecal calprotectin: Beyond intestinal organic diseases. Panminerva Med. 60, 29\u201334 (2018).","journal-title":"Panminerva Med."},{"key":"51580_CR44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/1055-9965.EPI-03-0160","volume":"13","author":"A Poullis","year":"2004","unstructured":"Poullis, A., Foster, R., Shetty, A., Fagerhol, M. K. & Mendall, M. A. Bowel inflammation as measured by fecal calprotectin. Cancer Epidemiol. Biomark. Prev. 13, 279\u2013284 (2004).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"51580_CR45","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1097\/MIB.0000000000000349","volume":"21","author":"M Calafat","year":"2015","unstructured":"Calafat, M. et al. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis. Inflamm. Bowel Dis. 21, 1072\u20131076 (2015).","journal-title":"Inflamm. Bowel Dis."},{"key":"51580_CR46","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1053\/j.gastro.2010.11.058","volume":"140","author":"JD Lewis","year":"2011","unstructured":"Lewis, J. D. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 140, 1817-1826.e2 (2011).","journal-title":"Gastroenterology"},{"key":"51580_CR47","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3109\/00365529209011186","volume":"27","author":"AG R\u00f8seth","year":"1992","unstructured":"R\u00f8seth, A. G., Fagerhol, M. K., Aadland, E. & Schj\u00f8nsby, H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand. J. Gastroenterol. 27, 793\u2013798 (1992).","journal-title":"Scand. J. Gastroenterol."},{"key":"51580_CR48","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000201441","volume":"58","author":"AG R\u00f8seth","year":"1997","unstructured":"R\u00f8seth, A. G., Aadland, E., Jahnsen, J. & Raknerud, N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 58, 176\u2013180 (1997).","journal-title":"Digestion"},{"key":"51580_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/1450970","volume":"2017","author":"S Kittanakom","year":"2017","unstructured":"Kittanakom, S. et al. Comparison of fecal calprotectin methods for predicting relapse of pediatric inflammatory bowel disease. Can. J. Gastroenterol. Hepatol. 2017, 1\u201310 (2017).","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"51580_CR50","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1515\/cclm-2012-0386","volume":"51","author":"L Coorevits","year":"2013","unstructured":"Coorevits, L., Baert, F. J. & Vanpoucke, H. J. M. Faecal calprotectin: Comparative study of the Quantum Blue rapid test and an established ELISA method. Clin. Chem. Lab. Med. 51, 825\u2013831 (2013).","journal-title":"Clin. Chem. Lab. Med."},{"key":"51580_CR51","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/jgh.12578","volume":"29","author":"K Inoue","year":"2014","unstructured":"Inoue, K. et al. Usefulness of a novel and rapid assay system for fecal calprotectin in pediatric patients with inflammatory bowel diseases. J. Gastroenterol. Hepatol. 29, 1406\u20131412 (2014).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"51580_CR52","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.cgh.2017.06.007","volume":"15","author":"A Heida","year":"2017","unstructured":"Heida, A. et al. Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity. Clin. Gastroenterol. Hepatol. 15, 1742-1749.e2 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"51580_CR53","doi-asserted-by":"publisher","first-page":"546","DOI":"10.5217\/ir.2018.00052","volume":"16","author":"S-C Wei","year":"2018","unstructured":"Wei, S.-C., Tung, C.-C., Weng, M.-T. & Wong, J.-M. Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intest. Res. 16, 546\u2013553 (2018).","journal-title":"Intest. Res."},{"key":"51580_CR54","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S1542-3565(05)00980-8","volume":"4","author":"K Takeuchi","year":"2006","unstructured":"Takeuchi, K. et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4, 196\u2013202 (2006).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"51580_CR55","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder, K. W., Tremaine, W. J. & Ilstrup, D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317, 1625\u20131629 (1987).","journal-title":"N. Engl. J. Med."},{"key":"51580_CR56","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best, W. R., Becktel, J. M., Singleton, J. W. & Kern, F. Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study. Gastroenterology 70, 439\u2013444 (1976).","journal-title":"Gastroenterology"},{"key":"51580_CR57","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi, J., Silverberg, M. S., Vermeire, S. & Colombel, J.-F. The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut 55, 749\u2013753 (2006).","journal-title":"Gut"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51580-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51580-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51580-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T16:31:40Z","timestamp":1705595500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51580-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51580"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-51580-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2821380\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"15 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1653"}}